On January 9, 2026, Bright Minds Biosciences Inc. completed its underwritten offering of 1,945,000 common shares in the capital of Bright Minds at a price of US$90.00 per common share for gross proceeds of US$175,050,000.

In connection with the offering, Bright Minds granted the underwriters a 30-day option to purchase up to an additional 15 percent of the common shares issued in the offering. The offering was conducted through a prospectus supplement to a shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission.

Jefferies, TD Cowen, Piper Sandler & Co., and Cantor acted as joint book-running managers for the offering.